跳至主要内容
临床试验/ACTRN12608000030370
ACTRN12608000030370尚未招募4 期

Effect of Isosorbide dinitrate(ISDN) and hydralazine(HYD) on left heart filling pressures in symptomatic systolic heart failure.

The Royal Melbourne Hospital0 个研究点目标入组 10 人开始时间: 2008年1月18日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • ·>18 year old
  • ·Non African background
  • ·Heart failure as defined by Left ventricular ejection fraction ( measured on TTE)< 45%New York Heart Association(NYHA) functional class II-III for at least 3 months
  • ·Pulmonary hypertension secondary to systolic heart failure ( Right Ventricular systolic pressure (RVSP) > 45mmHg on TTE)
  • ·On optimized and stable doses of traditional neurohormonal heart failure medications, Ace inhibitor(ACEI), Beta blockers and spironolactone for at least one month
  • ·Systolic blood pressure > 90mmHg

排除标准

  • ·Recent diagnosis( < 3 months) Acute myodcardial infarction(AMI), Congestive cardiac failure(CCF), percutaneous coronary intervention(PCI) or cardiac surgery.
  • ·Significant aortic or mitral stenosis
  • ·Concurrent illnesses likely to shorten life.

研究者

相似试验

Isosorbide dinitrate and hydralazine in symptomatic... | 临床试验